Baxter International BAX Pharmaceuticals — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's pharmaceuticals — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's pharmaceuticals — net sales?
- Baxter International (BAX) reported pharmaceuticals — net sales of $621M in Q1 2026.
- How has Baxter International's pharmaceuticals — net sales changed year-over-year?
- Baxter International's pharmaceuticals — net sales increased by 6.9% year-over-year, from $581M to $621M.
- What is the long-term trend for Baxter International's pharmaceuticals — net sales?
- Over 3 years (2021 to 2025), Baxter International's pharmaceuticals — net sales has grown at a 2.9% compound annual growth rate (CAGR), from $2.29B to $2.49B.
- What does pharmaceuticals — net sales mean?
- Total revenue earned by the Pharmaceuticals segment after accounting for returns and discounts.
- How do you interpret pharmaceuticals — net sales?
- Higher sales indicate strong market adoption and growth, while declining sales may signal competitive pressure or product lifecycle maturity.
- How does pharmaceuticals — net sales compare across companies?
- Benchmarkable against other pharmaceutical and medical supply segments in the healthcare industry.